Concerta vs Ritalin vs Focalin: Methylphenidate Formulations Explained

Concerta, Ritalin and Focalin all treat ADHD with methylphenidate, the same stimulant first approved in the U.S. in 1955. They differ in how the drug is released and in which form of the molecule they contain. Ritalin is short-acting and usually taken two or three times a day; Concerta is a once-daily extended-release tablet whose effects in children's studies were maintained through 12 hours; Focalin contains only dexmethylphenidate, the more active of methylphenidate's two mirror-image forms, so its doses are lower.

None of them is the strongest or the best in general. The right one depends on how many hours of coverage you need, whether you can swallow a tablet whole, how your body handles peaks and dips, what your pharmacy can supply and what your plan covers. The choice and any change belong with your prescriber.

The main options side by side

All of these contain a Schedule II controlled substance and carry the same boxed warning about abuse, misuse and addiction.

Ritalin: short-acting and flexible

Immediate-release methylphenidate reaches its peak blood level about 2 hours after a 10 mg tablet. The adult label describes dosing two or three times a day, with a maximum daily total set on the label, and suggests taking the last dose before 6 p.m. for people whose sleep is affected. Doses are set by the prescriber.

Short-acting tablets are useful when someone needs coverage only for part of the day, needs a schedule that varies from day to day, or is just starting and needs to find a dose. The trade-offs are more pills, more chances to forget a midday dose, and more ups and downs as each dose rises and wears off. A prescriber may sometimes pair a short-acting dose with a long-acting product, but that combination is an individual decision.

Concerta: one tablet, long day

Concerta is designed to release methylphenidate gradually over the day. After a dose, blood levels reach an initial peak at about 1 hour and then rise gradually over the next 5 to 9 hours, with average peak times between 6 and 10 hours. Its label states that once-daily Concerta minimizes the peaks and troughs seen with immediate-release methylphenidate taken three times a day. In its pediatric trials, improvements in attention and behavior were maintained through 12 hours after the dose.

Concerta's 2025 FDA labeling describes the design: osmotic pressure pushes the drug out at a controlled rate through a laser-drilled opening in a semipermeable membrane, and an immediate-release drug coating on the outside dissolves within about an hour to give an initial dose. Relexxii, another osmotic extended-release methylphenidate tablet, describes a similar system in its current label. This design explains several practical rules for Concerta:

• It must be swallowed whole with liquid; splitting, crushing or chewing compromises the extended release and may affect safety.
• The tablet does not change shape in the gut, so it is not ordinarily used in people with severe narrowing of the digestive tract.
• You may notice something that looks like a tablet in your stool; the label tells patients not to be concerned.

For people new to methylphenidate, the label describes starting at a low once-daily dose and increasing in weekly steps if needed, up to a maximum that differs for children 6 to 12 and for people 13 to 65. Those steps are set by the prescriber, who weighs benefit against side effects at each visit.

People switching from immediate-release methylphenidate start Concerta at a dose based on their current regimen, using a conversion table in the label, and the prescriber adjusts from there.

Focalin and Focalin XR: the more active form of methylphenidate

Standard methylphenidate is a racemic mixture, meaning an equal mix of two mirror-image forms, and the d-form is the more pharmacologically active one. Dexmethylphenidate, sold as Focalin, is that d-threo form alone. That is why the Focalin label starts people already taking methylphenidate at half their total daily methylphenidate dose. A lower milligram dose does not, by itself, make it more or less effective.

Focalin XR uses beads: half the dose is released right away and half later, producing two distinct peaks about 4 hours apart. Compared with Focalin tablets given twice 4 hours apart, the XR capsule produced fewer peak-and-trough swings. People taking Focalin tablets can generally be moved to the same daily dose of Focalin XR, per its label. Ritalin LA uses the same half-and-half bead approach for standard methylphenidate, with two peaks about 4 hours apart.

Because dexmethylphenidate's half-life is short (about 3 hours in healthy adults), the duration of any product depends heavily on its release system rather than on the drug itself.

Timing at a glance

The labels describe timing in different ways, so the comparison below uses each label's own measure rather than a single "hours of effect" number. Your experience may differ, and how long a dose feels effective is something to track and report.

How the labels handle a switch between products

Moving between methylphenidate products is common, and the labels give prescribers starting points rather than exact equivalents for everyone:

These are label starting points. The prescriber then adjusts based on how you respond, usually over weeks, and some switches need a slower approach. Never convert doses yourself, and do not combine leftover tablets from an old prescription with a new product.

Generic Concerta: why some generics were treated differently

Generic versions of Concerta have a more complicated history than most generics. In November 2014, FDA changed the therapeutic-equivalence rating of two generic Concerta tablets, made by Mallinckrodt and Kudco, from AB (substitutable) to BX (not enough data to confirm equivalence), after concerns that they might not be therapeutically equivalent to the brand. In October 2016, FDA proposed withdrawing approval of those two products because neither firm had withdrawn its product or provided data confirming bioequivalence; at that time FDA said they were still approved and could be prescribed but were not recommended for automatic substitution at the pharmacy. The process has since moved on: FDA withdrew approval of the Mallinckrodt product (now held by its subsidiary SpecGx) as of 18 June 2026, at the company's request, and in August 2026 announced a formal hearing on its proposal to withdraw the Kremers Urban (formerly Kudco) product.

The practical lesson is narrow. If you notice a clear change in how a long-acting stimulant works after a refill, check the manufacturer on the label and tell your prescriber rather than adjusting the dose yourself. The broader question is covered in generic vs brand-name psychiatric medications.

Patches, chewables, evening doses and newer formulations

Several newer methylphenidate products solve specific practical problems:

The patch has its own practical rules. Its label advises keeping heat sources such as heating pads and hair dryers away from the patch while it is worn, and allows removing it earlier than 9 hours if a shorter effect is wanted or late-day side effects appear.

Azstarys is unusual in its scheduling: the dexmethylphenidate in it is Schedule II, while serdexmethylphenidate on its own is Schedule IV. Newer products are often more expensive and may need prior authorization; see prior authorization for psychiatric medications.

Shortages and what your pharmacy can fill

Supply has been a real constraint. When checked on 26 October 2026, the FDA drug shortage database listed methylphenidate extended-release tablets (the Concerta type) as a current shortage, first posted in July 2023, with some manufacturers' strengths unavailable and others limited. The methylphenidate patch has also been listed as a current shortage since February 2025. Because the listing varies by strength and manufacturer, one pharmacy may be able to fill a prescription that another cannot. Steps to take are in what to do if your pharmacy is out, and cost strategies in lowering prescription costs.

Side effects and safety checks

All of these products share methylphenidate's warnings. In adults on Concerta, the most common side effects in trials were decreased appetite, headache, dry mouth, nausea, insomnia, anxiety, dizziness, weight loss, irritability, fast heart rate and excessive sweating. The labels also warn about:

• Risks in people with serious heart disease, and rises in blood pressure and heart rate.
• Slowed growth in children, so height and weight are monitored.
• Circulation problems in the fingers and toes, including Raynaud's phenomenon.
• Prolonged, painful erections, which need immediate medical attention.
• New or worsening tics; prescribers check for tics and Tourette's syndrome before starting.

Side effects can differ by formulation even when the drug is the same. A product that is still active at bedtime may disrupt sleep, while one that wears off abruptly may cause late-afternoon irritability. Those patterns are often fixed by changing the formulation or timing rather than abandoning methylphenidate; see when ADHD medication stops working. Blood pressure and heart monitoring are covered in ADHD medication and your heart.

Choosing among them: questions for your prescriber

If methylphenidate in any form does not work or is not tolerated, the next question is the stimulant family itself, covered in methylphenidate vs amphetamine, or a non-stimulant, covered in stimulant vs non-stimulant medication. Do not swap formulations, split extended-release tablets or change doses on your own.

How Dr. Lewis's team approaches ADHD medication

The practice offers an ADHD assessment for children and adults, in person or by telehealth, ending with a review-of-findings session, a written summary and a personalized treatment plan. Plans may include lifestyle changes, nutrition, psychotherapy, executive-function coaching, and medications when appropriate, and the practice provides ongoing medication management. More is on the ADHD treatment for children page and the ADHD assessment page. For other decisions about care, see the choosing psychiatric care guide.

Frequently asked questions

Is Focalin stronger than Ritalin?

Focalin contains only the more active form of methylphenidate, so it is given at lower doses; the label starts people switching from methylphenidate at half their daily dose. That does not make it more effective for everyone. Your prescriber handles any conversion.

Can I cut a Concerta tablet in half?

No. The label says to swallow it whole with liquid and not to split, crush or chew it, because that compromises the extended release. If the dose needs adjusting, ask your prescriber about a different strength.

Why does Concerta seem to wear off early for me?

Timing, sleep, food and dose all affect how long a long-acting stimulant seems to last, and a change in manufacturer can matter too. Track when it starts and fades and bring that to your prescriber rather than adding doses yourself.

Is generic Concerta the same as brand Concerta?

In 2014 FDA downgraded two specific generic Concerta products to a rating that means they are not automatically substitutable, and in 2016 it proposed withdrawing them. Approval of the Mallinckrodt product was withdrawn in June 2026, and the other is the subject of an FDA hearing. If you notice a clear change after a refill, check the manufacturer and tell your prescriber.

Can adults use the Daytrana patch?

Daytrana is FDA-approved for ages 6 to 17. Use in adults would be off-label and is a prescriber decision. For other options, see Adderall vs Vyvanse.

Which methylphenidate is best for a child who cannot swallow pills?

Options include opening Ritalin LA or Focalin XR capsules onto applesauce, a chewable or orally disintegrating extended-release tablet, or the patch. A pediatric prescriber can match the option to the child; see child psychiatrist vs pediatrician for ADHD.

Sources

1. Ritalin (methylphenidate hydrochloride) tablets prescribing information. Sandoz / DailyMed (NLM), 2023. dailymed.nlm.nih.gov
2. Ritalin LA (methylphenidate HCl) extended-release capsules prescribing information. Novartis / DailyMed (NLM), 2025. dailymed.nlm.nih.gov
3. Concerta (methylphenidate HCl) extended-release tablets prescribing information. Janssen Pharmaceuticals / DailyMed (NLM), 2026. dailymed.nlm.nih.gov
4. Focalin (dexmethylphenidate hydrochloride) tablets prescribing information. Sandoz / DailyMed (NLM), 2025. dailymed.nlm.nih.gov
5. Focalin XR (dexmethylphenidate hydrochloride) extended-release capsules prescribing information. Novartis / DailyMed (NLM), 2025. dailymed.nlm.nih.gov
6. Daytrana (methylphenidate transdermal system) prescribing information. Noven Therapeutics / DailyMed (NLM), 2025. dailymed.nlm.nih.gov
7. Jornay PM (methylphenidate HCl) extended-release capsules prescribing information. Ironshore Pharmaceuticals / DailyMed (NLM), 2025. dailymed.nlm.nih.gov
8. Azstarys (serdexmethylphenidate and dexmethylphenidate) capsules prescribing information. Commave / DailyMed (NLM), 2026. dailymed.nlm.nih.gov
9. Relexxii (methylphenidate HCl) extended-release tablets prescribing information. Vertical Pharmaceuticals / DailyMed (NLM), 2025. dailymed.nlm.nih.gov
10. Cotempla XR-ODT (methylphenidate) extended-release orally disintegrating tablets prescribing information. Neos Therapeutics / DailyMed (NLM), 2026. dailymed.nlm.nih.gov
11. QuilliChew ER (methylphenidate HCl) extended-release chewable tablets prescribing information. Tris Pharma (NextWave Pharmaceuticals) / DailyMed (NLM), 2026. dailymed.nlm.nih.gov
12. Methylphenidate Hydrochloride Extended Release Tablets (generic Concerta) made by Mallinckrodt and Kudco. U.S. Food and Drug Administration, 2021. fda.gov
13. FDA Drug Shortages Database: methylphenidate hydrochloride ER tablets; methylphenidate ER film. U.S. Food and Drug Administration, 2026. dps.fda.gov
14. 21 CFR 1308.12 Schedule II. Electronic Code of Federal Regulations (DEA), 2026. ecfr.gov
15. Concerta (methylphenidate HCl) extended-release tablets prescribing information, revised 09/2025. Janssen Pharmaceuticals / U.S. Food and Drug Administration (Drugs@FDA), 2025. accessdata.fda.gov
16. SpecGx LLC; Withdrawal of Approval of Abbreviated New Drug Application for Methylphenidate Hydrochloride Extended-Release Tablets, 27 Milligrams, 36 Milligrams, and 54 Milligrams. Food and Drug Administration, Federal Register (FR Doc. 2026-12236), 2026. federalregister.gov
17. Kremers Urban Pharmaceuticals, Inc.; Grant of Hearing Request Regarding a Proposal To Withdraw Approval of an Abbreviated New Drug Application for Extended-Release Methylphenidate Tablets. Food and Drug Administration, Federal Register (FR Doc. 2026-16536), 2026. federalregister.gov

Educational information, not medical, tax or legal advice. Decisions about diagnosis, medication and treatment belong with a clinician who knows your history.